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OBJECTIVES: To compare, in daily practice, the resource con-
sumption in the treatment of severe sepsis with multiple organ
failures, using either standard care alone or with drotrecogin alfa
(DA). METHODS: A pre-post study was conducted between
September 2002 and February 2005, before and after DA’s
market introduction. Selection bias was taken into account using
an optimal propensity score (PS) matching. Logistic regression
was used for the PS, missing values were handled using multiple
imputation. The medical procedures’ burden was assessed using
relative cost index (ICR) points. Acquisition costs, national
tariffs and a regression equation were used for drugs, transfu-
sions and hospital costs respectively. Cost comparisons were
made using 3 tests (Wilcoxon, lognormal t-test and bootstrap).
RESULTS: 1096 patients were included in the study and the PS
matching procedure retained 840 of them. DA treated patients
received more technical medical procedures (p = 0.0013). They
also had an increased length of stay in intensive care units (24.4
days against 21.3 days—p = 0.0018) and higher drug prescrip-
tion costs (€2004 1,773.16 in the before versus €2004 9,139.61
in the after phase), DA’s costs included (p < 0.0001). Moreover,
the anti-infective drugs and corticosteroid costs were signiﬁ-
cantly higher for DA treated patients (p < 0.0001 for both) and
costs linked to transfusions were higher (€2004 1,042.95 against
€2004—p = 0.0060), essentially due to a higher consumption of
packed red blood cells and fresh frozen plasma in the after phase.
The overall hospitalization costs reached €2004 36,718.39 in the
before and €2004 48,510.11 per patient in the after phase (p 
< 0.0001). CONCLUSIONS: PS matching ensures less biased
cost comparisons. The additional cost linked to DA prescription
is not reducible to its price. DA treated patients will also have
more technical medical procedures, an increased length of stay
and drug consumption as well as more transfusions.
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Voriconazole (VOR), a triazole antifungal, has been shown to
provide a superior clinical response and a survival beneﬁt com-
pared with conventional amphotericin B (CAB) as initial therapy
for proven or probable invasive aspergillosis (IA). Liposomal
amphotericin B (L-AmB), is used to achieve the therapeutic effect
of CAB while minimizing renal toxicity. OBJECTIVE: To
compare the cost-effectiveness of VOR versus L-AmB as initial
therapy for IA. METHODS: The cost-effectiveness of VOR
versus L-AmB was assessed through a decision-analytic model in
terms of cost per success and per survival. Economic and clini-
cal data for VOR and CAB were obtained from a large clinical
trial comparing the two treatments over 12 weeks (Herbrecht et
al, NEJM 2002). Data for CAB were modiﬁed to reﬂect the lower
toxicity and better outcomes of L-AmB using a published meta-
analysis. 12-week results were extrapolated over lifetime using
Markov cycles. The impact of uncertainty in input parameters
was evaluated by means of probabilistic sensitivity analysis.
RESULTS: Expected average health care costs were £27,165
(95% uncertainty distribution, £20,532–£34.071) for VOR 
and £33,113 (£26,703–£40,136) for L-AmB at 12 weeks and
£32,949 (£26,025–£41,216) and £45,552 (£38,005–£60,897)
over the lifetime for the two treatments, respectively. Mean sur-
vival was 174 life-weeks (160–190) for VOR and 128 life-weeks
(111–147) for L-AmB. Voriconazole was expected to be domi-
nant to L-AmB, (greater effectiveness and less costly) in terms of
success at 12 weeks, survival at 12 weeks, and life-weeks gained
(probability >80%). Using different unit costs and different
source data for efﬁcacy of L-Amb, VOR remained cost-effective.
CONCLUSIONS: This economic evaluation suggests that
voriconazole is cost saving with better predicted outcomes and
therefore a dominant cost-effective treatment of IA compared
with L-AmB in the UK.
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INTRODUCTION: Routine inﬂuenza vaccination is fully reim-
bursed in most European countries for people aged over 65 years
and those at high risk of complications. Lowering the age thresh-
old for routine vaccination would reduce hospitalisations and
deaths, as well as productivity losses during inﬂuenza outbreaks.
We performed an economic evaluation of lowering the current
age thresholds of 59 in Germany, and 64 in France, Italy, and
Spain to age 50 in these countries. METHODS: A decision ana-
lytic model was developed comparing a new policy providing
universal reimbursement with current policy covering only those
at high risk of complications in the 50–59/64 age group. We
analysed costs and outcomes one over one inﬂuenza season from
the perspectives of third-party payers (TPP) and society. The
primary effectiveness measure was quality-adjusted life-years
(QALYs). Model inputs were obtained from the published liter-
ature, complemented by expert opinion. Deterministic and prob-
abilistic sensitivity analyses (PSA) were conducted. The value of
acquiring additional information was explored. RESULTS: The
estimated ICERs ranged from €13,156 to €28,568 per QALY
gained from the TPP perspective. At a threshold of €50,000 per
QALY gained, the probabilities of the new policy being cost-
effective would be 93% for France, 72% for Germany, 89% for
Italy, and 95% for Spain. From the societal perspective, the cost
per QALY decreased to €9,318 in France and €4,195 in Spain,
while cost savings are predicted for Germany and Italy. The
greatest sources of uncertainty were ILI incidence rate, vaccine
uptake, fatality rate and costs of vaccination. CONCLUSIONS:
Routine inﬂuenza vaccination for people over 50 is likely to be
cost-effective in France, Germany, Italy and Spain, and cost-
saving from the societal perspective in Germany and Italy. The
scope to reduce decision uncertainty is limited, as much of this
stems from the unpredictable ﬂuctuation in annual ILI incidence
rate.
